About Michael Silber

This author has not yet filled in any details.
So far Michael Silber has created 1944 blog entries.

California

The Medi-Cal Rx Web Portal has been updated with the following:  

Also in California, for Medi-Cal Rx updates, please visit the Department of Health Care Services’ Medi-Cal Rx: Transition website and the Medi-Cal Rx website. Medi-Cal Rx pharmacy stakeholders are strongly encouraged to sign-up for urgent announcements and other updates as they are posted to the Medi-Cal Rx website. Medi-Cal Rx will be effective January 1, 2022.  

Also in California, the Board of Pharmacy released the following Notices of Modified Text: 

Comments are due December 18 and can be submitted to Lori Martinez . 

Finally in California, This is a reminder that under SB 212 (2018), which established a prescription drug and sharps take-back program in California, retail pharmacies that sell a covered drug under their own label must submit written notification to the Board of Pharmacy identifying the covered entity from which the retail pharmacy obtains the covered product.  

“Covered entity” is defined under SB 212 as a manufacturer of covered products that are sold into the state. If there is not a manufacturer for a covered product, then the covered entity is the distributor of the covered product sold into the state. If there is not a manufacturer or distributor for a covered product, then the covered entity is the owner or licensee of a trademark or brand name under which covered products are sold into the state. If there is not a manufacturer, distributor, or owner or licensee of trademark or brand name, then the covered entity is the importer of the covered product into the state. 

Please click here to view the relevant provision in statute – Public Resources Code Section 42031(b).  

We have been made aware that few pharmacies required to report this information have not done so. If applicable, this is a reminder to please submit this information to the Board of Pharmacy’s Executive Officer, Anne Sodergren, at anne.sodergren@dca.ca.gov and lilly.fang@dca.ca.gov.  

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

2021-12-10T12:16:07-05:00December 10, 2021|California|

Colorado

The Department of Health Care Policy and Financing (HCPA) issued an Operational Memo informing Health First Colorado (Medicaid) providers of their obligation to effectively communicate coordination of benefits requirements to Health First Colorado members who have primary third party insurance.

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2021-12-10T12:13:50-05:00December 10, 2021|Colorado|

District of Columbia

The Department of Health approved a final rule requiring reporting of vaccines by all providers, including pharmacies, with 24 hours of vaccine administration to the registry. The rule will be effective when published in the DC Register.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

2021-12-10T12:12:27-05:00December 10, 2021|District of Columbia|

Florida

Rule 64B16-28.108 related to labeling of Medicinal Drugs by pharmacy permits has been revised by the Board of Pharmacy and became effective November 28, 2021.  The revision is primarily for Institutional Class II, Modified Class II Type B, or Class III permits that are labeling patient specific medications.

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

2021-12-10T12:11:37-05:00December 10, 2021|Florida|

Georgia

The Department of Public Health would like to hear from pharmacies who may be interested in providing the FDA approved COVID-19 therapeutic pill, Molnupiravir. Please take a minute to complete this COVID-19 Molnupiravir Pharmacy Interest Survey. 

If you would like to learn more about Merck’s Molnupiravir pill, CLICK HERE to watch a 30-minute presentation by Lisley Brooks B.S., Doctor of Pharmacy Candidate 2022 and Tracy Dabbs, PharmD, Georgia Department of Public Health. 

For more information, contact NACDS’ Leigh Knotts at 803-243-7207.

2021-12-10T12:10:37-05:00December 10, 2021|Georgia|

Iowa

On December 6, the Board of Pharmacy transitioned to a new payment platform (Gov2Go) for online applications. Additional information about the Iowa eGovernment portal, Gov2Go, was posted later this week. For faster access to Gov2Go, please create a Gov2Go account at web.gov2go.com. If you experience any payment issues while applying for a new license/registration or renewing an existing license/registration, please contact Terry Witkowski.

Also in Iowa, the Department of Public Health (IDPH) posted a NEW Vaccine Information Brief (12.10.21) with update on the vaccine allocation survey on December 13 that  will not include Pfizer Adolescent/Adult Vaccine in order to utilize existing inventory in the state and FDA expands eligibility for Pfizer-BioNTech COVID-19 Booster Dose to Individuals 16 and 17 years of age. Also note last week’s Vaccine Information Brief (12.3.21) announcing ACIP COVID-19 Vaccine Booster Recommendation, Moderna Shelf-Life Extension Update and Updated – Interim Clinical Considerations for Use of COVID-19 Vaccines and this week’s Vaccine Information Brief (12.8.21) with information about Pfizer transition to Comirnaty. Please direct questions to the COVID-19 Vaccine Call Center at 1-800-831-6293 ext. 1 or email 

Also in Iowa, the Department of Human Services, Iowa Medicaid Enterprise, issued INFORMATIONAL LETTER NO. 2295-MC-FFS announcing the alignment between Managed Medicaid and Medicaid Fee-for-Service to limit the number of diabetic needles that member may obtain per month. The managed care organizations currently allow 100 needles per month. Members enrolled in Medicaid Fee-for-Service were also be limited to 100 diabetic needles per month effective December 1, 2021.  

Finally in Iowa, the Department of Human Services, Iowa Medicaid Enterprise, issued INFORMATIONAL LETTER NO. 2291-MC-FFS announcing several Medicaid Pharmacy Program Changes effective January 1, 2022, related to the following: 

  • Changes to the Preferred Drug List (PDL);  
  • Pharmacy benefit policy changes for albumin human, papaverine injection solution and Zoladex subcutaneous implant;  
  • New Drug Prior Authorization (PA) Criteria for non-biologic agents for ulcerative colitis, Vericiguat (Verquvo) and Viloxazine (Qelbree)  
  • Changes to Existing PA Criteria for Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, Oral [formerly Elagolix Products], Omalizumab (Xolair) and Topical Acne and Rosacea Products 
  • Point of Sale Billing Updates (ProDUR Quantity Limits) and  
  • DUR Update 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2021-12-10T12:09:31-05:00December 10, 2021|Iowa|

Kentucky

The Board of Pharmacy approved an emergency amendment to the pharmacy closure regulation at its Nov. 30 meeting. As an emergency regulation, once it is filed with the LRC it will be in effect immediatelyThe regulation changes the temporary pharmacy closure notification requirement from 5 days to 2 two days within a 14-day period or 9 days in a 30-day period and requires pharmacies to notify the board in immediately in writing of a closure meeting the threshold. Additionally, it has requirements for signage, control of prescriptions, notification of providers and post-closure claims adjudication.

For more information, contact NACDS’ Jill McCormack at 717-592-8977.

2021-12-10T12:07:54-05:00December 10, 2021|Kentucky|

Missouri

The Department of Commerce and Insurance (DCI) Board of Pharmacy issued a bulletin on Vaccine Provider Healthcare Assistance in response to the Board of Pharmacy received regarding if pharmacies can use non-pharmacy healthcare providers to help provide both COVID-19 and non-COVID-19 vaccines.

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2021-12-10T12:07:10-05:00December 10, 2021|Missouri|

Nebraska

The Department of Health and Human Services announced the next COVID-19 Medicaid Provider call will take place on December 15 at noon (Central).  

Also in Nebraska, the Department of Health and Human Services (DHHS) updated the Janssen COVID-19 Vaccine Administration – Booster – Code: 0034A — $37.25 (effective November 2, 2021). DHHS also published its Provider Bulletin 21-21 – November 2021 COVID-19 Vaccines Updates, including COVID-19 booster doses and COVID-19 vaccinations for children. For questions, contact Medicaid.

Finally in Nebraska, the COVID rates have been added and been moved from the right-hand navigation list to the main list on the Department of Health and Human Service Medicaid Provider Rates and Fee Schedules website.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2021-12-10T12:06:19-05:00December 10, 2021|Nebraska|
Go to Top